Company Valuation: Bolt Biotherapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 182.7 48.96 42.52 20.48 10.5 7.513 - -
Change - -73.2% -13.15% -51.84% -48.75% -28.42% - -
Enterprise Value (EV) -3.524 -97.32 -39.45 20.48 10.5 7.513 7.513 7.513
Change - -2,661.37% 59.46% 151.92% -48.75% -28.42% 0% 0%
P/E -1.65x -0.55x -0.61x -0.32x -0.31x -0.17x -0.19x -0.13x
PBR 0.73x 0.29x 0.38x - - - - -
PEG - 0x 0x 0.03x 0x -0x 0x -0x
Capitalization / Revenue 145x 8.55x 5.4x 2.66x 1.36x 37.6x 2.15x 0.94x
EV / Revenue -0x -0x -0x 0x 0x 37.6x 2.15x 0.94x
EV / EBITDA - - - - - - - -
EV / EBIT 0x 0x 0x -0x -0x -0.12x -0.16x -0.13x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -59.4 -47.2 -36.6 -33 -17.85 -23.36 -20.19 -30.84
Distribution rate - - - - - - - -
Net sales 1 1.26 5.729 7.876 7.69 7.695 0.2 3.5 8
EBITDA -83.1 -79.08 -65.12 - - - - -
EBIT 1 -92.79 -90.32 -76.2 -73.05 -36.11 -65 -47.5 -60
Net income 1 -98.59 -88.1 -69.2 -63.12 -33.38 -47.4 -47.5 -60
Net Debt -186.2 -146.3 -81.97 - - - - -
Reference price 2 98.000 26.000 22.400 10.702 5.468 3.900 3.900 3.900
Nbr of stocks (in thousands) 1,864 1,883 1,898 1,914 1,919 1,926 - -
Announcement Date 3/30/22 3/29/23 3/21/24 3/24/25 3/12/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-0.17x - - - 7.51M
20.25x7.04x14.2x1.45% 67.98B
36.9x9.64x29.44x0.04% 64.94B
-77.3x14.92x-71.95x-.--% 27.58B
-15.85x6.12x-7.7x-.--% 26.06B
29.69x6.35x16.48x-.--% 25.74B
27.41x5.13x17.06x-.--% 20.09B
49.41x18.23x36.98x0.31% 17.16B
1289.22x37.23x812.54x-.--% 14.92B
18.23x5.44x12.69x-.--% 14.62B
Average 137.78x 12.23x 95.53x 0.2% 27.91B
Weighted average by Cap. 82.01x 10.35x 51.60x 0.38%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. BOLT Stock
  4. Valuation Bolt Biotherapeutics, Inc.